NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
原披露日期：2026-10-26；精度：分钟。
来源原始时间字段：2026-10-26T10:00:16.000Z
本站首次发现：未知，原记录未留存；不以本次页面访问时间补造。
首次资格通过：2026-10-27T12:00:33.978Z；首次公开：2026-10-27T12:00:33.978Z；公开模式：rule_backfill；自然时槽：2026-10-27T11:00:23.513Z。
来源：SEC（SEC EDGAR 6-K）。事件标题沿用来源原题，分类依据是标题明确披露的事件；计划、申请、签署和完成状态以原题及原文为准，未据此推断后续结果。
查看原始披露 ↗原文限定：In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) 17.8 months median Overall Survival Exploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatment Investigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology
原文限定：Preliminary Efficacy
原文限定：Overall, the acceptable safety profile and early efficacy observed by investigators in these preliminary findings provide promising signals of activity and warrant further evaluation in larger randomized trials.
本站核验来源归属、证券身份及披露时间，不保证公司陈述或投资价值。